Tag Archives: forecasts

Sprint beats revenue and profit forecasts, shares rise

Sprint beats revenue and profit forecasts, shares riseSprint, which is awaiting regulatory approval for a merger with bigger rival T-Mobile US Inc, said it added a net 109,000 subscribers who pay a monthly bill during the second quarter, down from 168,000 new subscribers at the same time last year. It fell short, however, of estimates for it to add 22,000 net phone subscribers, instead losing 34,000 in the quarter as it battles the perception that it is struggling to keep up with investment by AT&T Inc and Verizon Communications Inc. Sprint reported net income attributable to the company of $ 196 million, or 5 cents per share, in the quarter ended Sept. 30, compared with a net loss of $ 48 million, or 1 cent per share, a year earlier.



Yahoo News – Latest News & Headlines

JP Morgan beats Street 2Q forecasts

JP Morgan beats Street 2Q forecastsNEW YORK (AP) _ JPMorgan Chase & Co. (JPM) on Friday reported second-quarter earnings of $ 7.03 billion.



Yahoo News – Latest News & Headlines

Higher margins and new drugs help GlaxoSmithKline beat forecasts

Signage for GlaxoSmithKline is seen on it's offices in London, BritainBy Ben Hirschler LONDON (Reuters) – Improving margins in consumer health and growing demand for new drugs lifted GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016. The results may help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines offsetting a decline in sales of aging lung treatment Advair.



Sexual Health News Headlines – Yahoo! News

Higher margins and new drugs help GlaxoSmithKline beat forecasts

Signage for GlaxoSmithKline is seen on it's offices in London, BritainBy Ben Hirschler LONDON (Reuters) – Improving margins in consumer health and growing demand for new drugs lifted GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016. The results may help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines offsetting a decline in sales of aging lung treatment Advair.



Sexual Health News Headlines – Yahoo! News

GSK flags up pipeline as HIV drugs help it beat profit forecasts

A jogger runs past a signage for pharmaceutical giant GlaxoSmithKline in LondonGlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. Strong sales of Tivicay and Triumeq validated GSK's decision in May to keep its HIV business, rather than spinning it off, and offset a further slide in revenue from lung drug Advair and lower group profit margins following a major business overhaul. The drugmaker recently sold its marketed cancer drugs to Novartis and bought the Swiss group's vaccines, while increasing its consumer health business through a joint venture.



Sexual Health News Headlines – Yahoo! News

Merck quarterly earnings beat forecasts

A view of the Merck & Co. campus in Linden, New Jersey(Reuters) – Merck & Co reported better-than-expected quarterly earnings despite the negative impact of the stronger dollar, with strong sales growth of its vaccines and treatments for diabetes and HIV. The No. 2 U.S. drugmaker on Friday said it earned $ 1.79 billion, or 58 cents per share, in the second quarter. That compared with $ 2.02 billion, or 65 cents per share, in the year-earlier period. Excluding special items, the company earned $ 1.05 per share. Analysts, on average, had expected $ 1.01 per share. Company sales rose 1 percent to $ 12.31 billion, topping Wall Street expectations of $ 12. …



Sexual Health News Headlines – Yahoo! News